Cipher Pharmaceuticals Inc
TSX:CPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Pfeiffer Vacuum Technology AG
XETRA:PFV
|
DE |
|
H
|
Hwaxin Environmental Co Ltd
SZSE:301265
|
CN |
|
B
|
BW Energy Ltd
OSE:BWE
|
BM |
|
Atp Ticari Bilgisayar Agi ve Elektrik Guc Kaynaklari Uretim Pazarlama ve Ticaret AS
IST:ATATP.E
|
TR |
Cipher Pharmaceuticals Inc
PP&E Net
Cipher Pharmaceuticals Inc
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cipher Pharmaceuticals Inc
TSX:CPH
|
PP&E Net
$453k
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
4%
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
PP&E Net
$2.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
6%
|
CAGR 10-Years
4%
|
|
|
Canopy Growth Corp
TSX:WEED
|
PP&E Net
CA$285m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
21%
|
|
|
Cronos Group Inc
TSX:CRON
|
PP&E Net
$147.3m
|
CAGR 3-Years
33%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
54%
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
PP&E Net
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
PP&E Net
CA$21.9m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
Cipher Pharmaceuticals Inc
Glance View
Cipher Pharmaceuticals, Inc. engages as a specialty pharmaceutical company, which have diversified portfolio of commercial and early to late-stage products. The company is headquartered in Oakville, Ontario. The company went IPO on 2004-02-25. The firm acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products directly in Canada and indirectly through partners in the United States, Canada and South America. Its Dermatology products include Actikerall, Epuris, Ozanex, and Vaniqa. Its Hospital Acute Care products are Aggrastat and Brinavess. The Company’s Out-Licensed Products include Absorica, ConZip, Durela, and Lipofen. The company is focused on three strategy that includes acquisitions, in-licensing, and selective investments in drug development to assemble a portfolio of prescription products that serve unmet medical needs. The firm's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC and Cipher Pharmaceuticals US LLC.
See Also
What is Cipher Pharmaceuticals Inc's PP&E Net?
PP&E Net
453k
USD
Based on the financial report for Sep 30, 2025, Cipher Pharmaceuticals Inc's PP&E Net amounts to 453k USD.
What is Cipher Pharmaceuticals Inc's PP&E Net growth rate?
PP&E Net CAGR 10Y
4%
Over the last year, the PP&E Net growth was -47%. The average annual PP&E Net growth rates for Cipher Pharmaceuticals Inc have been -3% over the past three years , -26% over the past five years , and 4% over the past ten years .
